Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Receivables (2023 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Receivables for 4 consecutive years, with $62.8 million as the latest value for Q1 2026.

  • For Q1 2026, Receivables rose 141.4% year-over-year to $62.8 million; the TTM value through Mar 2026 reached $62.8 million, up 141.4%, while the annual FY2025 figure was $66.1 million, 642.48% up from the prior year.
  • Receivables hit $62.8 million in Q1 2026 for Syndax Pharmaceuticals, up from $40.1 million in the prior quarter.
  • Across five years, Receivables topped out at $62.8 million in Q1 2026 and bottomed at $1.2 million in Q4 2023.
  • Average Receivables over 4 years is $27.2 million, with a median of $26.0 million recorded in 2025.
  • Year-over-year, Receivables skyrocketed 815.81% in 2024 and then surged 141.4% in 2026.
  • Syndax Pharmaceuticals' Receivables stood at $1.2 million in 2023, then surged by 815.81% to $11.2 million in 2024, then soared by 257.23% to $40.1 million in 2025, then soared by 56.48% to $62.8 million in 2026.
  • According to Business Quant data, Receivables over the past three periods came in at $62.8 million, $40.1 million, and $27.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.